Eupraxia Pharmaceuticals Inc.
EPRX
$7.51
-$0.07-0.92%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 17.10M | 12.41M | 12.16M | 11.68M | 10.92M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 38.43M | 29.75M | 29.14M | 27.43M | 27.00M |
| Operating Income | -38.43M | -29.75M | -29.14M | -27.43M | -27.00M |
| Income Before Tax | -38.59M | -29.41M | -29.03M | -26.36M | -25.74M |
| Income Tax Expenses | 19.10K | 9.60K | 10.20K | -400.00 | 1.80K |
| Earnings from Continuing Operations | -38.61 | -29.42 | -29.04 | -26.35 | -25.74 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 29.60K | 42.90K | 82.90K | 132.80K | 242.00K |
| Net Income | -38.58M | -29.37M | -28.96M | -26.22M | -25.50M |
| EBIT | -38.43M | -29.75M | -29.14M | -27.43M | -27.00M |
| EBITDA | -38.27M | -29.60M | -29.01M | -27.32M | -26.89M |
| EPS Basic | -1.00 | -0.88 | -0.86 | -0.76 | -0.77 |
| Normalized Basic EPS | -0.58 | -0.51 | -0.51 | -0.46 | -0.47 |
| EPS Diluted | -1.00 | -0.88 | -0.86 | -0.76 | -0.77 |
| Normalized Diluted EPS | -0.58 | -0.51 | -0.51 | -0.46 | -0.47 |
| Average Basic Shares Outstanding | 159.82M | 144.17M | 142.87M | 142.57M | 135.70M |
| Average Diluted Shares Outstanding | 159.82M | 144.17M | 142.87M | 142.57M | 135.70M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |